Vestal Point Capital, LP Travere Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.9 Trillion
- Q2 2025
A detailed history of Vestal Point Capital, LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 355,000 shares of TVTX stock, worth $10.5 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
355,000Holding current value
$10.5 Million% of portfolio
0.28%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
236Shares Held
103MCall Options Held
1.71MPut Options Held
401K-
Janus Henderson Group PLC London, X09.54MShares$283 Million0.07% of portfolio
-
Armistice Capital, LLC New York, NY8.88MShares$263 Million2.3% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$227 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$178 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C35.1MShares$151 Million0.1% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.9B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...